Related Experiment Videos
Should hemoglobin be normalized in uremic patients?
1Department of Nephrology, Salford Royal Hospitals NHS Trust, UK. robert.foley@srht.nhs.uk
Insights
Cardiovascular disease is common in chronic kidney disease (CKD) patients, with anemia being a key risk factor. Managing hemoglobin levels may improve quality of life and reduce cardiac issues in CKD.
Area of Science:
- Nephrology
- Cardiology
- Internal Medicine
Background:
- Cardiovascular disease (CVD) is prevalent in chronic kidney disease (CKD), leading to significantly higher mortality rates.
- Patients on dialysis face 10-20 times higher cardiovascular death rates than the general population.
- Cardiac failure is the most common reason for hospitalization in dialysis patients within 5 years of starting therapy.
Purpose of the Study:
- To explore the link between anemia and cardiovascular complications in CKD.
- To investigate the role of hemoglobin management in improving outcomes for CKD patients.
Main Methods:
- Review of experimental and clinical studies on cardiovascular system in uremia.
- Analysis of prospective observational studies on anemia as a risk factor in CKD progression.
- Examination of intervention trials on anemia management and cardiovascular outcomes.
Main Results:
- Anemia is an independent risk factor for cardiovascular overload, left ventricular enlargement, failure, and death in CKD.
- Observational studies support normalizing hemoglobin for improved left ventricular size, quality of life, and survival.
- Intervention trials suggest benefits in quality of life and reduced cardiac remodeling with physiological anemia management.
Conclusions:
- The cardiovascular system in uremia exhibits premature senescence, poorly tolerating hemodynamic stress.
- Anemia and hypertension are key modifiable factors contributing to cardiovascular complications in CKD.
- While benefits in quality of life and cardiac remodeling are suggested, definitive evidence on reducing cardiac failure and death from anemia management in CKD is still pending.
Abstract:
Cardiovascular disease is virtually a sine qua non of chronic kidney disease, as is poor quality of life. Dialysis patient for example, have cardiovascular death rates 10 - 20 times those of the general population. Recent estimates indicate that at least half of all patients starting dialysis therapy will have an admission for a major cardiovascular event within 5 years, of which cardiac failure is the most common. Both experimental and clinical studies suggest that the cardiovascular system in uremia is in a state of premature senescence, one which is poorly suited to the supraphysiological hemodynamic demands to which it is subjected. Most patients develop cardiomyopathy, which clearly predisposes to cardiac decompensation. Anemia and hypertension are the most obvious modifiable overload parameters in uremic patients. Several prospective observational studies have demonstrated anemia to be an independent risk factor for each step in the process leading from hemodynamic overload, through maladpative left ventricular enlargement to left ventricular failure and death. This process starts with declining renal function, long before end-stage renal disease, the traditional time at which intervention has started to be seriously considered. The case for normal hemoglobin in patients with chronic kidney disease is still greatly disputed. Observational studies, which examine left ventricular size, quality of life, functional status, hospitalization and survival, are overwhelmingly supportive. Intervention trials, to date, suggest clear benefits of a physiological approach to anemia management in terms of quality of life, and likely benefits in terms of left ventricular stress minimisation and associated remodelling. Whether these translate into a reduction in outcomes like cardiac failure or death remains an unanswered question.